Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
ASP Isotopes Inc. completed its previously announced acquisition of Renergen Limited on January 6, 2026. ASP Isotopes acquired all issued Renergen ordinary shares via a South African court-approved scheme of arrangement, paying with shares of its own common stock.
Renergen shareholders received 0.09196 ASP Isotopes common shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 new ASP Isotopes shares. Following the deal, Renergen became a direct, wholly owned subsidiary, and its shares will be delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes stock remains listed on Nasdaq and the JSE.
Renergen executives are joining ASP Isotopes’ leadership, with CEO Stefano Marani becoming President, Electronics and Space, and COO Nick Mitchell becoming Co-Chief Operating Officer. The consideration shares were issued in an unregistered transaction relying on Rule 802, and ASP Isotopes plans to file required acquired-business financial statements and pro forma information in a later amendment.
ASP Isotopes Inc. reports that the South African Takeover Regulation Panel has issued a compliance certificate for its planned acquisition of Renergen Limited. This clears a key regulatory step so the South African law scheme of arrangement can proceed to implementation. Under the Scheme, Renergen shareholders are to receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The company outlines a detailed timetable through early January 2026, including suspensions of Renergen trading on the JSE and ASX, the listing of ASP Isotopes consideration shares, the Scheme implementation date, settlement of new shares, and payment of cash for fractional entitlements. The disclosure also highlights cross-border settlement mechanics and reiterates risks that the Scheme may not be implemented as anticipated or that expected benefits from the Renergen acquisition may not be realized.
ASP Isotopes Inc. reported that, on December 17, 2025, it obtained all required regulatory approvals and clearances for its proposed offer to acquire all of the issued ordinary shares of Renergen Limited.
The transaction is structured as a scheme of arrangement under South African law, under which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date. The company also issued a press release describing the receipt of these approvals.
ASP Isotopes Inc. reported a leadership update. Founder and Executive Chairman Paul Mann will resume his role as the company’s Chief Executive Officer, while continuing as Executive Chairman, after a temporary leave of absence. His return to the dual role is effective January 19, 2026. The company disclosed this change in connection with a press release dated December 2, 2025.
ASP Isotopes Inc. (ASPI) is asking stockholders to vote at its virtual 2025 annual meeting on December 18, 2025. Investors are being asked to elect two Class III directors, Sipho N. Maseko and Todd Wider, M.D., to new three-year terms and to ratify EisnerAmper LLP as independent auditor for the year ending December 31, 2025. Only holders of common stock at the October 27, 2025 record date, when 110,840,122 shares were outstanding, may vote, with one vote per share.
The company highlights that six of seven directors are Nasdaq‑defined independent and describes an active audit, compensation, and nominating/governance committee structure. A new non‑employee director pay policy provides a $100,000 annual cash retainer plus equity awards. For 2024, Executive Chairman Paul Mann received total compensation of about $4.77 million, including salary, bonus, and restricted stock. Directors and executives together beneficially own 14.4% of outstanding shares.
ASP Isotopes Inc. filed a Form 8-K to furnish an investor presentation connected to its previously announced quarterly business update conference. On November 21, 2025, the company released a "Third Quarter Update Call" presentation, dated as of November 2025, which is attached as Exhibit 99.1. The information in the presentation is provided as of November 2025, and the company states it does not assume any obligation to update it. The material is furnished under Regulation FD and is expressly not deemed "filed" for purposes of certain liability provisions of the federal securities laws.
ASP Isotopes Inc. insider activity: The Interim CEO and COO reported selling 67,500 shares of common stock of ASP Isotopes Inc. on 11/17/2025 at a weighted average price of $7.507 per share. After this transaction, the executive beneficially owns 1,579,693 shares.
The filing explains that the sale was a "sell to cover" transaction made under a Rule 10b5-1 trading plan adopted on June 9, 2025, to cover tax withholding obligations tied to the vesting of restricted stock awards. The shares were sold in multiple trades at prices ranging from $7.215 to $7.85.
ASP Isotopes Inc. (ASPI) reports third-quarter 2025 results reflecting early commercial traction but very heavy losses as it scales its isotope and nuclear fuels platform.
Total revenue reached $4.9 million for the quarter and $7.2 million for the first nine months of 2025, up from $2.95 million a year earlier, driven by both product and new construction services revenue. However, high research and development plus selling, general and administrative costs led to a nine‑month net loss of $96.5 million, compared with $23.2 million in the prior‑year period.
The balance sheet expanded significantly, with cash and cash equivalents of $113.9 million and total assets of $225.9 million as of September 30, 2025, supported by two common stock offerings in June and July 2025 and additional capital raised in October and November. Convertible notes payable at fair value increased to $98.0 million, and total stockholders’ equity rose to $96.6 million.
ASP Isotopes has begun commercial production at two enrichment facilities in South Africa and is preparing initial shipments of enriched C‑12, Si‑28 and C‑14 between late 2025 and the first half of 2026, while also producing Yb‑176 samples. The company is planning additional plants in South Africa, Iceland and the U.S., pursuing a uranium‑235 nuclear fuel initiative, a pending acquisition of Renergen, and a planned spin‑off and U.S. listing of its Quantum Leap Energy (QLE) business, for which a confidential S‑1 has been submitted.
ASP Isotopes Inc. reported that it will host a quarterly business update conference call and webcast on November 21, 2025 at 8:30 a.m. Eastern Time. The company disclosed this plan in a current report and attached the related press release as an exhibit, noting that the call will provide a regular update on its business activities. The press release is furnished for information purposes and is not treated as filed under securities law.
ASP Isotopes Inc. reports that its wholly owned subsidiary Quantum Leap Energy LLC plans to issue approximately $64.3 million of unsecured convertible promissory notes to accredited and non-U.S. investors. The QLE 2025 Notes bear 8.0% annual interest, with principal and interest due on demand by majority noteholders on or after the five-year anniversary of the initial closing. QLE expects to use the net proceeds to build and develop laser enrichment production facilities and for general corporate purposes.
Existing 2024 convertible notes will automatically convert into QLE 2025 Notes at the initial closing, without additional proceeds to QLE or ASPI. The notes convert into equity upon a stock exchange listing, a qualifying equity financing of at least $20 million, certain corporate transactions, or at maturity, generally at a 20% discount or a valuation-based price formula. Holders who do not convert in a qualifying corporate transaction are entitled to unpaid interest plus 1.5× principal. A registration rights agreement will grant demand and piggyback registration rights, including the ability to demand an initial public offering if QLE has not gone public within five years.